Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

PHASE3TerminatedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

April 27, 2021

Study Completion Date

June 20, 2023

Conditions
Neoplasms, Head and Neck
Interventions
DRUG

feladilimab

feladilimab is available as an intravenous infusion.

DRUG

Pembrolizumab

Pembrolizumab is available as an intravenous infusion.

DRUG

Placebo

Placebo is available as an intravenous infusion.

Trial Locations (163)

8

GSK Investigational Site, Dublin

112

GSK Investigational Site, Taipei

333

GSK Investigational Site, Taoyuan

833

GSK Investigational Site, Kaohsiung City

1900

GSK Investigational Site, La Plata

2010

GSK Investigational Site, Darlinghurst

2065

GSK Investigational Site, St Leonards

2148

GSK Investigational Site, Blacktown

3000

GSK Investigational Site, Melbourne

3084

GSK Investigational Site, Heidelberg

4029

GSK Investigational Site, Herston

5021

GSK Investigational Site, Bergen

6009

GSK Investigational Site, Nedlands

8091

GSK Investigational Site, Zurich

9007

GSK Investigational Site, Sankt Gallen

10002

GSK Investigational Site, Taipei

10060

GSK Investigational Site, Candiolo

11490

GSK Investigational Site, Taipei

12200

GSK Investigational Site, Berlin

13620

GSK Investigational Site, Seongnam-si, Gyeonggi-do

15232

GSK Investigational Site, Pittsburgh

15706

GSK Investigational Site, Santiago de Compostela

19111

GSK Investigational Site, Philadelphia

20010

GSK Investigational Site, Washington D.C.

20133

GSK Investigational Site, Milan

20141

GSK Investigational Site, Milan

20246

GSK Investigational Site, Hamburg

21565

GSK Investigational Site, Incheon

22087

GSK Investigational Site, Hamburg

25123

GSK Investigational Site, Brescia

25279

GSK Investigational Site, Saltillo

28046

GSK Investigational Site, Madrid

28204

GSK Investigational Site, Charlotte

28223

GSK Investigational Site, Pozuelo de Alarcón/Madrid

29010

GSK Investigational Site, Málaga

29425

GSK Investigational Site, Charleston

29607

GSK Investigational Site, Greenville

31059

GSK Investigational Site, Toulouse

33000

GSK Investigational Site, Bordeaux

33705

GSK Investigational Site, St. Petersburg

37045

GSK Investigational Site, Legnago (VR)

37203

GSK Investigational Site, Nashville

37404

GSK Investigational Site, Chattanooga

44680

GSK Investigational Site, Guadalajara

44805

GSK Investigational Site, Saint-Herblain

46009

GSK Investigational Site, Valencia

46202

GSK Investigational Site, Indianapolis

47014

GSK Investigational Site, Meldola (FC)

49100

GSK Investigational Site, Petah Tikva

49241

GSK Investigational Site, Busan

50006

GSK Investigational Site, Changhua

50009

GSK Investigational Site, Zaragoza

52074

GSK Investigational Site, Aachen

52621

GSK Investigational Site, Ramat Gan

54622

GSK Investigational Site, Thessaloniki

54645

GSK Investigational Site, Thessaloniki

58128

GSK Investigational Site, Hwasun,Jeollanam-do

59000

GSK Investigational Site, Lille

59322

GSK Investigational Site, Valenciennes

67200

GSK Investigational Site, Strasbourg

69373

GSK Investigational Site, Lyon

71110

GSK Investigational Site, Heraklion,Crete

72000

GSK Investigational Site, Le Mans

74370

GSK Investigational Site, Epagny Metz-Tessy

75005

GSK Investigational Site, Paris

89075

GSK Investigational Site, Ulm

91010

GSK Investigational Site, Duarte

91120

GSK Investigational Site, Jerusalem

98108

GSK Investigational Site, Seattle

111123

GSK Investigational Site, Moscow

150000

GSK Investigational Site, Harbin

150054

GSK Investigational Site, Yaroslavl

188663

GSK Investigational Site, Poselok Kuzmolovsky

196603

GSK Investigational Site, Pushkin

197022

GSK Investigational Site, Saint Petersburg

198255

GSK Investigational Site, Saint Petersburg

200126

GSK Investigational Site, Shnghai

200347

GSK Investigational Site, Craiova

230001

GSK Investigational Site, Hefei

233000

GSK Investigational Site, Bengbu

330029

GSK Investigational Site, Nanchang

400015

GSK Investigational Site, Cluj-Napoca

407280

GSK Investigational Site, Floreşti

410469

GSK Investigational Site, Oradea

430022

GSK Investigational Site, Wuhan

440055

GSK Investigational Site, Satu Mare

500283

GSK Investigational Site, Brasov

510060

GSK Investigational Site, Guangzhou

510503

GSK Investigational Site, Guangzhou

530021

GSK Investigational Site, Nanning

550000

GSK Investigational Site, Guiyang

610000

GSK Investigational Site, Chengdu

610041

GSK Investigational Site, Chengdu

700106

GSK Investigational Site, Iași

720284

GSK Investigational Site, Suceava

900591

GSK Investigational Site, Constanța

02215

GSK Investigational Site, Boston

C1125ABD

GSK Investigational Site, Ciudad Autónoma de Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

J5402DIL

GSK Investigational Site, San Juan

29043-260

GSK Investigational Site, Vitória

88034-000

GSK Investigational Site, Florianópolis

14784-400

GSK Investigational Site, Barretos

15090-000

GSK Investigational Site, São José do Rio Preto

30150-221

GSK Investigational Site, Belo Horizonte, Minas Gerais

01246-000

GSK Investigational Site, São Paulo

04014-002

GSK Investigational Site, São Paulo

T2N 4N2

GSK Investigational Site, Calgary

T6G 1Z2

GSK Investigational Site, Edmonton

V5Z 4E6

GSK Investigational Site, Vancouver

L8V 5C2

GSK Investigational Site, Hamilton

M5G 1Z5

GSK Investigational Site, Toronto

H2X 3E4

GSK Investigational Site, Montreal

H3T 1E2

GSK Investigational Site, Montreal

G1J 1Z4

GSK Investigational Site, Québec

G5L 5T1

GSK Investigational Site, Rimouski

DK-2100

GSK Investigational Site, Copenhagen

04103

GSK Investigational Site, Leipzig

D09 V2N0

GSK Investigational Site, Dublin

260-8717

GSK Investigational Site, Chiba

277-8577

GSK Investigational Site, Chiba

791-0280

GSK Investigational Site, Ehime

812-8582

GSK Investigational Site, Fukuoka

060-8648

GSK Investigational Site, Hokkaido

673-8558

GSK Investigational Site, Hyōgo

305-8576

GSK Investigational Site, Ibaraki

761-0793

GSK Investigational Site, Kagawa

259-1143

GSK Investigational Site, Kanagawa

981-1293

GSK Investigational Site, Miyagi

951-8520

GSK Investigational Site, Niigata

028-3695

GSK Investigational Site, Numakunai

534-0021

GSK Investigational Site, Osaka

362-0806

GSK Investigational Site, Saitama

411-8777

GSK Investigational Site, Shizuoka

113-8431

GSK Investigational Site, Tokyo

113-8519

GSK Investigational Site, Tokyo

6229 HX

GSK Investigational Site, Maastricht

3015 GD

GSK Investigational Site, Rotterdam

0379

GSK Investigational Site, Oslo

85-796

GSK Investigational Site, Bydgoszcz

81-519

GSK Investigational Site, Gdynia

44-101

GSK Investigational Site, Gliwice

31-826

GSK Investigational Site, Krakow

10-228

GSK Investigational Site, Olsztyn

97-200

GSK Investigational Site, Tomaszów Mazowiecki

02-781

GSK Investigational Site, Warsaw

3000-075

GSK Investigational Site, Coimbra

1649-035

GSK Investigational Site, Lisbon

4454-509

GSK Investigational Site, Matosinhos Municipality

4200-072

GSK Investigational Site, Porto

4200-319

GSK Investigational Site, Porto

021389

GSK Investigational Site, Bucharest

075100

GSK Investigational Site, Otopeni

02841

GSK Investigational Site, Seoul

03080

GSK Investigational Site, Seoul

05505

GSK Investigational Site, Seoul

120-752

GSK Investigational Site, Seoul

08035

GSK Investigational Site, Barcelona

08908

GSK Investigational Site, Barcelona

M20 4BX

GSK Investigational Site, Manchester

SW3 6JJ

GSK Investigational Site, London

NG5 1PB

GSK Investigational Site, Nottingham

SM2 5PT

GSK Investigational Site, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT04128696 - Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter